Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31044942 | 0.88 | NPC1 (0.45) | GPR84NPC1GALR3NR2F2RAB9A | |
| SCHEMBL31044754 | 0.85 | RAB9A (0.44) | NPC1GALR3NR2F2RAB9AALDH1A1 | |
| SCHEMBL31045064 | 0.83 | NPC1 (0.42) | GPR84NPC1GALR3NR2F2RAB9A | |
| SCHEMBL31044923 | 0.82 | CRHR1 (0.37) | NPC1GALR3NR2F2RAB9ACNR1 | |
| SCHEMBL31044932 | 0.81 | NPC1 (0.39) | HPGDNPC1GALR3NR2F2RAB9A | |
| SCHEMBL31045140 | 0.81 | NPC1 (0.45) | NPC1GALR3NR2F2RAB9AALDH1A1 | |
| SCHEMBL31044664 | 0.81 | NPC1 (0.37) | NPC1GALR3NR2F2RAB9APRKCI | |
| SCHEMBL31044686 | 0.80 | PDE4B (0.36) | NPC1GALR3NR2F2RAB9APRKCI | |
| SCHEMBL20668024 | 0.78 | KDM4E (0.44) | HPGDALDH1A1KDM4EHSD17B10KMT2A | |
| SCHEMBL20667996 | 0.78 | APP (0.46) | NPC1GALR3NR2F2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117968-A1 | THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS | SAINT LOUIS UNIVERSITY | 2022-04-21 | — | — | US | disclosed |
| WO-2019018359-A1 | THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS | SAINT LOUIS UNIVERSITY (US) | 2019-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117968-A1 | THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS | TYMS, DPYD, UMPS | GPR84 4501/4885AKT3 1328/4885HPGD 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.